BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8669855)

  • 1. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis.
    Eskelinen M; Hippeläinen M; Salmela E; Paajanen H; Alhava E; Syrjänen K
    Anticancer Res; 1992; 12(6B):2033-6. PubMed ID: 1295446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential diagnosis between benign and malignant biliary tract obstruction: discriminative usefulness of some clinical and laboratory data.
    Giusti G; Piccinino F; Sagnelli E; Pasquale G
    Acta Hepatogastroenterol (Stuttg); 1975 Dec; 22(6):374-9. PubMed ID: 1211064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of serum CA549, CA M26 and CA M29 levels in the post-operative follow-up of breast cancer patients.
    Nicolini A; Ferdeghini M; Colombini C; Carpi A
    J Nucl Med Allied Sci; 1990; 34(4):309-13. PubMed ID: 2090796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour markers in pancreatic cancer.
    Haglund C; Kuusela P; Roberts PJ
    Ann Chir Gynaecol; 1989; 78(1):41-53. PubMed ID: 2667448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
    Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
    Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of the tumour markers CA 195 and CEA in patients with adenocarcinoma of the pancreas.
    Taylor OM; Cooper EH; Benson EA; McMahon MJ
    Eur J Surg Oncol; 1992 Oct; 18(5):508-13. PubMed ID: 1426303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma.
    Lucarotti ME; Habib NA; Kelly SB; Rothnie ND; Nelson O; Lindholm L; Cooper MJ; Wood CB; Williamson RC
    Eur J Surg Oncol; 1991 Feb; 17(1):51-3. PubMed ID: 1995358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-associated trypsin inhibitor in pancreatic diseases.
    Aroasio E; Piantino P
    Scand J Clin Lab Invest Suppl; 1991; 207():71-3. PubMed ID: 1723534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value and limitations of neoplasm markers in the diagnosis of pancreatic carcinoma].
    Fabris C; Basso D; Meggiato T; Del Favero G; Fogar P; Panozzo MP; Ferrara C; Scalon P; Naccarato R
    Recenti Prog Med; 1991 Mar; 82(3):166-72. PubMed ID: 2047559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The concentration of carcinoembryonic antigen and carbohydrate antigen Ca-19-9 in the blood serum in cancerous diseases of the gastrointestinal tract].
    Mit'kov VV; Ogneva TV; Goriaĭnova II; Milanov S; Milkov V
    Med Radiol (Mosk); 1989 Nov; 34(11):22-4. PubMed ID: 2586258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A decision support system for predicting a recurrence of breast cancer; a prospective study of serum tumour markers TAG 12, CA 15-3 and MCA.
    Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P; Alhava E
    Anticancer Res; 1992; 12(5):1439-42. PubMed ID: 1444204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of tumour markers TAG 12 with CA 15-3 and MCA in breast cancer diagnosis.
    Eskelinen M; Hippelainen M; Salmela E; Paajanen H; Carlsson L; Jonsson P; Alhava E
    Anticancer Res; 1992; 12(1):39-42. PubMed ID: 1567179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Trials of the diagnostic potentials of TPA in tumorous and nontumorous lung pathologies in 303 cases].
    Aquilina R; Bergero F; Magri G; Noceti P; Mirabelli S
    Minerva Med; 1992; 83(7-8):415-9. PubMed ID: 1522964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic evaluation of alanine aminopeptidase as serum marker for detecting cancer.
    Severini G; Gentilini L; Tirelli C
    Cancer Biochem Biophys; 1991 Nov; 12(3):199-204. PubMed ID: 1688253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Laboratory diagnosis of tumors of the pancreato-biliary area in patients with mechanical jaundice].
    Skvortsov SV; Lytsar' BN; Kalinin AV; Dolinskiĭ AG
    Klin Med (Mosk); 1992; 70(5-6):21-3. PubMed ID: 1279265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnostic usefulness of Ca 19-9 antigen in cancer of the pancreas and neoplasms of the pancreato-biliary intersection].
    Robles-Diáz G; Aceves G; Galván E
    Gac Med Mex; 1990; 126(2):78-82; discussion 82-3. PubMed ID: 2387490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostic value of CA 19-9 and CEA in gastrointestinal pathology].
    Patai A; Héber S; Döbrönte Z; Kovács LG
    Orv Hetil; 1992 May; 133(21):1301-4, 1307. PubMed ID: 1603581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.